The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Determination of the maximum tolerated dose (MTD) of the CNS penetrant tyrosine kinase inhibitor (TKI) tesevatinib administered in combination with trastuzumab in HER2+ patients with metastatic breast cancer (BC).
 
Nancy U. Lin
Consulting or Advisory Role - Novartis
Research Funding - Array BioPharma; Genentech; Geron; GlaxoSmithKline; Kadmon; Novartis
 
Rachel A. Freedman
Research Funding - Eisai (Inst); Genentech (Inst); Puma Biotechnology (Inst)
 
Kathy Miller
Consulting or Advisory Role - Clovis Oncology; ImClone Systems; Incyte; Nektar; Tesaro
Research Funding - Clovis Oncology (Inst); EntreMed (Inst); Genentech (Inst); ImClone Systems (Inst); Macrogenics (Inst); Medivation (Inst); Merrimack (Inst); Novartis (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Komal L. Jhaveri
Consulting or Advisory Role - Dara Biosciences; Genentech; Samus Therapeutics
 
David A. Eiznhamer
Employment - Kadmon
Research Funding - Kadmon
 
Mark S. Berger
Employment - Deciphera; Kadmon
Leadership - Deciphera; Kadmon
Stock and Other Ownership Interests - Deciphera; Kadmon
 
Erika Paige Hamilton
No Relationships to Disclose